uniQure N.V. (QURE) vs Rapport Therapeutics, Inc. Common Stock (RAPP)
A side-by-side comparison of uniQure N.V. and Rapport Therapeutics, Inc. Common Stock across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
QURE
uniQure N.V.
$23.06HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
RAPP
Rapport Therapeutics, Inc. Common Stock
$31.15HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — QURE vs RAPP
growth of $100 · dividends reinvested · last 2yQURE +319.9% (+104.9%/yr)RAPP +54.8% (+24.4%/yr)QURE compounded faster over this window
QURE RAPP
QURE vs RAPP: by the numbers
- •QURE is the larger company ($1.60B vs $1.49B market cap).
- •Both run net losses; RAPP's is the smaller (-685.80% vs -1350.73% net margin).
Metrics side by side
Valuation
| Metric | QURE | RAPP |
|---|---|---|
| P/S ratio | 85.67 | 74.49 |
| P/B ratio | 4.94 | 3.52 |
Profitability
| Metric | QURE | RAPP |
|---|---|---|
| Gross margin | 89.53% | 0.00% |
| Operating margin | -1166.77% | 0.00% |
| Net margin | -1350.73% | -685.80% |
| ROE | -77.83% | -32.43% |
| ROIC | -22.55% | -35.66% |
Growth (annualized)
| Metric | QURE | RAPP |
|---|---|---|
| Revenue CAGR (5Y) | -48.20% | N/A |
| Total return CAGR (5Y) | -6.16% | N/A |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.